Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Ovarian Cancer: early-phase trial registry
147 of 338 indexed Ovarian Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #20 of 28,707 conditions by registered trial count.
338 US clinical trials · 147 currently recruiting · #20 of 28,707 conditions by registered trial count
Ovarian Cancer: 338 US clinical trials tracked, 147 recruiting.
Ovarian Cancer is the subject of 338 registered US clinical trials on ClinicalTrials.gov, 147 of them currently open to new participants. 28 are in Phase 3-4 (later-stage) and 230 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 31 of these trials.
Enrollment posture brief
Registry condition ovarian-cancer
OPEN 147 | RECR 43% | LATE 28 | EARLY 230 | RANK #20 | SPON 31
Volume-matched condition peers
Nearest open-share peer: Cigarette Smoking (43% recruiting · 46 trials)
Ovarian Cancer lists 147 open slots (43% of 338 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Ovarian Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Ovarian Cancer is recruiting above its size-band peers.
147 of 338 indexed trials (43.5%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Ovarian Cancer trials is spread across many organizations.
Memorial Sloan Kettering Cancer Center accounts for 31 of 338 trials (9.2%). 186 distinct sponsors appear on at least one study for this condition label.
-
Typical Ovarian Cancer enrolment sits around 86 participants.
Median target enrolment is 86 among the 323 trials that report a genuine target (sentinel values excluded). 172 of those (53.3%) plan for fewer than 100 participants.
-
Ovarian Cancer research is mostly interventional.
297 interventional and 41 observational studies make up this index (87.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
338 total, page 1 of 7
Transvaginal Ultrasonography as a Screening Method for Ovarian Cancer
John R van Nagell
NCT04473833
Avera Cancer Sequencing and Analytics Protocol (ASAP)
Avera McKennan Hospital & University Health Center
NCT05142033
Sample Collection for Ongoing Research and Product Evaluation Study
Natera
NCT07318051
Use of the CA 125 Algorithm for the Early Detection of Ovarian Cancer in Low Risk Women
M.D. Anderson Cancer Center
NCT00539162
Specimen and Data Study for Ovarian Cancer Early Detection and Prevention
Northwestern University
NCT00005095
Genetic & Pathological Studies of BRCA1/BRCA2: Associated Tumors & Blood Samples
Stanford University
NCT01034033
Evaluating an Evidence-Based Family History Screening Program Adapted to Increase Reach and Uptake of Screening for BRCA-Associated Cancers in Rural Public Health Clinics
Emory University
NCT06760507
Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer
Mayo Clinic
NCT05051722
TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention
University Medical Center Nijmegen
NCT04294927
UNTOLD Ovarian Cancer Unmet Needs Survey
Masonic Cancer Center, University of Minnesota
NCT07070726
The DETECT Study: Discovery and Evaluation of Testing for Endometrial and Ovarian Cancer in Tampons
University of Alabama at Birmingham
NCT03538665
EXoPERT EMERALD Clinical Study
EXoPERT
NCT07186296
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
National Cancer Institute (NCI)
NCT01441089
Video Education With Result Dependent dIsclosure
Dana-Farber Cancer Institute
NCT05225428
Identifying Underserved Individuals inTexas With Hereditary Cancer Risk Using Mobile Mammography Units and Telegenetics.
M.D. Anderson Cancer Center
NCT05649072
Improving Nutrition and Physical Activity for Cancer Survivors (Tools To Be Fit)
University of California, San Francisco
NCT05056077
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
Merck Sharp & Dohme
NCT07318558
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
Merck Sharp & Dohme
NCT06824467
Comprehensive Outcomes for After Cancer Health
Pack Health
NCT05349227
A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
Regeneron Pharmaceuticals
NCT04590326
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
Daiichi Sankyo
NCT06819007
Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
The Netherlands Cancer Institute
NCT03772028
Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy
Genmab
NCT07225270
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
AbbVie
NCT05445778
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
AstraZeneca
NCT05797168
Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer
Imunon
NCT06915025
A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors
Eli Lilly and Company
NCT06238479
A Study Evaluating the Integrative Medicine at Home (IM@HOME) Program in People With Cancer
Memorial Sloan Kettering Cancer Center
NCT05053230
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
SystImmune
NCT05983432
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
Incyte Corporation
NCT07214779
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
AstraZeneca
NCT05123482
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
AstraZeneca
NCT05489211
Developing New Educational Materials About Genetic Testing for a Diverse Group of Cancer Patients
Memorial Sloan Kettering Cancer Center
NCT04751435
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
Artios Pharma
NCT04657068
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Eli Lilly and Company
NCT06465069
Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors
Conjupro Biotherapeutics
NCT07424547
18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
National Cancer Institute (NCI)
NCT06503146
A Study of XMT-1660 in Participants With Solid Tumors
Mersana Therapeutics
NCT05377996
A Study of Intra-operative Imaging in Women With Ovarian Cancer
Memorial Sloan Kettering Cancer Center
NCT04878094
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
PMV Pharmaceuticals
NCT04585750
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
National Cancer Institute (NCI)
NCT03412877
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
Xencor
NCT06276491
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
SystImmune
NCT06293898
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
Corcept Therapeutics
NCT06906341
A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors
OnCusp Therapeutics
NCT06234423
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
BeiGene
NCT06257264
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
Tubulis
NCT06303505
The SENTRY Study: Testing Whether Changes in Platelet RNA Enhance the Early Diagnosis of Ovarian Cancer
University of Utah
NCT06665945
REVITALIZE: RCT to Reduce Fatigue in Adults With Ovarian Cancer on PARP Inhibitors
Dana-Farber Cancer Institute
NCT06710548
Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
Whitehawk Therapeutics
NCT07444814
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 143 |
| Phase 2 | 87 |
| Phase 3 | 25 |
| Phase 4 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Ovarian Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Ovarian Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Ovarian Cancer page
338 registered trials, 147 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 147 Ovarian Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Memorial Sloan Kettering Cancer Center sponsors the most Ovarian Cancer trials on record, review their full trial history before evaluating a specific study. See Memorial Sloan Kettering Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Ovarian Cancer condition card totals 338 registered trials; most-linked intervention Bevacizumab; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.